Supplementary Table ovarian cancer cell lines



Download 284 Kb.
Date08.07.2018
Size284 Kb.
Supplementary Table S1. Ovarian cancer cell lines

Cell line

Histology

Characterizationa

Treatment(s)b

Xenograft

Sequencing data c,d

Reference

59M

Endometrioid

Ascites

Naïve




X

(Wilson et al.)

138D

Cystadeno-carcinoma

Ascites

Carboplatin







(Wilson et al.)

180D

Adeno-carcinoma

Ascites

Cisplatin, Carboplatin







(Wilson et al.)

200D

Adeno-carcinoma

Tumor tissue

Naïve







(Wilson et al.)

253D

Adeno-carcinoma

Ascites

Warfarin, Cyclophsphamide, medroxyprogestrone acetate







(Wilson et al.)

2008

2008 *C13

Cystadeno-carcinoma

Tumor tissue

Constant 1µM



Naïve







(Andrews et al.)

A1847

Adeno-carcinoma

Tumor tissue

Naïve







(Pirker et al.)

A2780

CP70*

C30*

C200*

ADR*

Adeno-carcinoma

Tumor tissue Intermittent 70µM

Constant 30µM

Constant 200µM

Adriamicin



Naïve

Yes

X

(Burbridge et al., Karlan et al., Shaw et al.)

Caov-3

Adeno-carcinoma

Tumor tissue

cyclophosphamide, adriamycin, and 5-fluorouracil

Yes

X

(Karlan et al.)

COLO704

Adeno-carcinoma

Ascites

Naïve




X

(Steinmeyer et al.)

COLO720E

Serous

Ascites

Naïve







(Taniguchi et al.)

COV318

Serous

Ascites

Naïve




X

(van der Berg-Baker et al.)

COV362

COV362.4

Endometrioid.

Colony of COV362 at passage 16



Pleural effusion

Naïve




X

(van der Berg-Baker et al.)

COV413A

Serous

Tumor tissue

Naïve







(van der Berg-Baker et al.)

COV413B

Serous

Tumor tissue

Naïve







(van der Berg-Baker et al.)

COV434

Granulosa

Tumor tissue

Naïve







(van der Berg-Baker et al.)

COV504

Serous

Pleural effusion

Naïve




X

(van der Berg-Baker et al.)

DOV13

Serous

Ascites




Yes




(Afzal et al., Ahmed et al., Rodriguez et al.)

EFO-21

Adeno-carcinoma

Ascites

Naïve




X

(Holzel et al.)

EFO-27

Adeno-carcinoma

Solid omental metastasis

Naïve




X

(Holzel et al.)

ES-2

Clear Cell

Tumor tissue

Naïve

Yes

X

(Lau et al., Shaw et al.)

Hey

A8

C2

Serous

Tumor tissue xenograft

Naïve

Yes

X

(Buick et al.)

ID-8, IG10, IF5

Mouse transformed ovary

Line developed from transformed mouse ovarian surface epithelial cells

Naïve

Yes




(Roby et al.)

(Greenaway et al., Urzua et al.)



IGROV-I

Endometrioid

S:III, Tumor tissue

Naïve




X

(Benard et al., Burbridge et al.)

MDAH2774

Endometrioid

Ascites

Naïve

Yes




(Freedman et al.)

MOSE

Mouse normal ovary

Mouse Ovarian tissue

Naïve







(Roby et al.)

MONTY1

Serous

Tissue

Naïve

Yes




(Kaur et al.)

OAW-28

Adeno-carcinoma

Ascites

Cisplatin, Melphalan




X

(Wilson et al.)

OAW-42

Cystadeno-carcinoma


Ascites - forms free-floating, platinum sensitive cysts in vitro.

Cisplatin




X

(Ahmed et al., Wilson et al.)

OC314

Serous-papillary cancer

Ascites. 39 yrs, FIGO IIIC, low differentiated ser.-pap

Naïve




X

(Alama et al.)

OC316

Adeno-carcinoma

Ascites. 60 yrs old, FIGO IV, low differentiated

Neo-adjuvant PEC-surgery-PEC, progression/chemo-resistant disease, taxol




X

(Alama et al.)

OV17R

Adeno-carcinoma

S:III, Ascites

Carboplatin, Cyproterone, Tamoxifen







(Boocock et al.)

OV25

Adeno-carcinoma

S:III, Ascites

Cyclophosphamide, Etoposide, Tamoxifen







(Boocock et al.)

OV25R

Adeno-carcinoma

S:III, Ascites

Cyclophosphamide, Etoposide, Tamoxifen







(Boocock et al.)

OV56

Serous

S:IV, Ascites

Carboplatin




X

(Boocock et al.)

OV58

Serous

S:III, Ascites

Carboplatin, Chlorambucil







(Boocock et al.)

OV7

Mixed

Tumor tissue, high grade

Chlorambucil




X

(Boocock et al.)

OV90

Serous

S:IIIC, G:3, Ascites

Naïve

Yes

X

(Boocock et al.)

OVCA429

Serous

Ascites




No




(Ahmed et al., Introna et al., Shaw et al.)

OVCA433

Serous

S:III, G:3, Ascites

Paclitaxel, carboplatin

Yes




(Ahmed et al., Introna et al., Shaw et al., van der Berg-Baker et al.)

OVCAR-3

Serous adeno-carcinoma

Ascites, NCI 60 cell line d

Cyclophosphamide, Adriamycin, Cisplatin

Yes

X

(Green et al., Hamilton et al., Yip et al.)

OVCAR-4

Adeno-carcinoma

Ascites, NCI 60 cell line d

Cyclophosphamide, Adriamycin, Cisplatin

Yes

X

(Green et al., Yip et al.)

OVCAR-5

Adeno-carcinoma

Tumor tissue, NCI 60 cell line d

Naïve

Yes




(Yip et al.)

OVMANA

Clear cell

Tumor tissue. 40 yrs old. FIGO IIB

Cisplatin

Yes, sq

X

(Cheung et al., Gorai et al.)

OVISE

Clear cell

Tumor tissue

Carboplatin

Yes, sq

X

(Cheung et al., Gorai et al.)

OVTOKO

Clear cell

Tumor tissue (spleen), FIGO IIIB

Carboplatin




X

(Cheung et al., Gorai et al.)

PEO23

Adeno-carcinoma

Ascites

Cisplatin, Chlorambucil







(Langdon et al.)

RMUG-S

RMUG-L

Adeno-carcinoma










X

(Sakayori et al.)

SKOV3

SKOV3ip.1

SKOV3x

SKOV3TR (taxane resistant)

Adeno-carcinoma

Ascites, NCI 60 cell line d

Thiotepa

Yes

X

(Hua et al., Shaw et al., Yip et al.) SKOV3ip.1 (Yu et al.) SKOV3x (Shao et al.) SKOV3TR (Landen et al.)

SW 626

Adeno-carcinoma

S:III, Tumor tissue

Naïve







(Giannakakou et al.)

TOV112D

Endometrioid

S:IIIC, G:3, Tumor tissue. P53 mutation. Very aggressive, 42 yr old pt. survived only 3 months.

Naïve

Yes

X

(Provencher et al.)

TOV21G

Clear cell

S:III, G:3, Tumor tissue. 42 yr old pt. P53 wt.

Naïve

Yes

X

(Provencher et al.)

TR175

Cystadeno-carcinoma

S:III, Ascites

Naïve







(Hill et al.)

TYK-nu

Clear cell

Cisplatin sensitive

Naïve

Yes

X

(Cheung et al.)

UCI101

Adeno-carcinoma

S:III, Ascites/ Tumor tissue

Cyclophosphamide, Adriamycin, Cisplatin, Taxol







(Fuchtner et al.)

UWB1.289
UWB1.289+BRCA1

Serous, mutated BRCA1 exon 11

BRCA1 restored



Tumor tissue

Platinum Refractory







(DelloRusso et al.)


a Stage, S; Grade, G; Tumor, cell line derived from solid tumor tissue; Ascites, cell line derived from ascetic fluid.

b Treatments were done before initial derivation of cell line. *Sub-lines of A2780. Sub-lines of Hey. Sub-lines of 2008.

c Sequencing information at http://www.broadinstitute.org/ccle/home and published by Barretina and colleagues (Barretina et al.). This website contains sequencing information on 50 ovarian cancer cell lines

d Sequencing information for the NCI 60 celllines is available at http://discover.nci.nih.gov/cellminer/home.do
References
1. Afzal, S. et al., 1985, MTI-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts: Human Pathology, v. 29, p. 155-180.

2. Ahmed, N. et al., 2002, Overexpression of avb6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade: Carcinogenesis, v. 23, no. 2, p. 237-244.

3. Alama, A. et al., 1996, Establishment and characterization if three new cell lines derived from the ascites of human ovarian carcinomas: Gynecologic Oncology, v. 62, p. 82-88.

4. Andrews, P. et al., 1985, Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by gluthatione depletion: Cancer Research, v. 45, p. 6250-6253.

5. Barretina, J. et al., 2012, The cancer cell line encyclopedia enables predictive modeling of anticancer drug sensitivity: Nature, v. 483, p. 603-607.

6. Benard, J. et al., 1985, Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice: Cancer Research, v. 45, p. 4970-4979.

7. Boocock, C. A. et al., 1995, Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma: Journal of the National Cancer Institute, v. 87, no. 7, p. 506-516.

8. Buick, R. N. et al., 1985, Comparative properties of five human ovarian adenocarcinoma cell lines: Cancer Research, v. 45, p. 3668-3676.

9. Burbridge, M. et al., 1999, Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: Use of the CA125 tumour marker to predict antitumour activity: International Journal of Oncology, v. 15, p. 1155-1162.

10. Cheung, H. W. et al., 2011, Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer: Proceedings of the National Academy of Sciences USA, v. 108, no. 30, p. 12372-12377.

11. DelloRusso, C. et al., 2013, Functional characterization of a novel BRCA1-null ovarian cancer cell lilne in response to ionizing radiation: Molecular Cancer Research, v. 5, p. 35-45.

12. Freedman, R. S. et al., 1978, Characterization of an ovarian carcinoma cell line: Cancer, v. 42, no. 5, p. 2352-2359.

13. Fuchtner, C. et al., 1993, Characterization of a human ovarian carcinoma cell lines: Gynecologic Oncology, v. 48, no. 2, p. 203-209.

14. Giannakakou, P. et al., 1997, Pacliaxel-resistant human ovarian cancer cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymerization: Journal of Biological Chemistry, v. 272, no. 27, p. 17118-17125.

15. Gorai, I. et al., 1995, Establishment of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with fifferent properties: Gynecologic Oncology, v. 57, p. 33-46.

16. Green, J. A. et al., 1984, Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by gluthatione depletion: Cancer Research, v. 44, p. 5427-5431.

17. Greenaway, J. et al., 2008, Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer: Gynecologic Oncology, v. 108, p. 385-394.

18. Hamilton, T. C. et al., 1983, Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors: Cancer Research, v. 43, p. 5379-5389.

19. Hill, B. T. et al., 1987, Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies: International Journal of Cancer, v. 39, p. 219-225.

20. Holzel, F. et al., 1983, Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones: Journal of the National Cancer Institute, v. 70, p. 839-845.

21. Hua, W. et al., 1995, SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth resistant to estrogens and antiestrogens: J Steroid Biochem Molec Biol, v. 55, p. 279-289.

22. Introna, M., and R. C. Bast, 1985, Epithelial ovarian carcinoma: Cell lines and antigenic tumor markers., in JMA Whitehouse and C.Williams ed., Cancer of the female reproductive system: John Wiley and Sons, p. 153-180.

23. Karlan, B. Y. et al., 1994, Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells: Gynecologic Oncology, v. 53, p. 70-77.

24. Kaur, S. et al., 2009, b3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer: American Journal of Pathology, v. 175, no. 5, p. 2184-2196.

25. Landen, C. N. et al., 2010, Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer: Molecular Cancer Therapeutics, v. 9, no. 12, p. 3186-3199.

26. Langdon, S. P. et al., 1988, Characterization and properties of 9 human ovarian carcinoma cell lines: Cancer Research, v. 48, p. 6166-6172.

27. Lau, D. H. M. et al., 1991, Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin: Cancer Research, v. 51, p. 5181-5187.

28. Pirker, R. et al., 1985, Characterization of immunotoxins active against ovarian cancer cell lines: Immunotox agasinst ovarian cancer, v. 76, p. 1261-1267.

29. Provencher, D. M. et al., 200, Characterization of four novel epithelial ovarian cancer cell lines: In Vitro Cell Dev Biol Anim, v. 36, no. 6, p. 357-361.

30. Roby, K. F. et al., 2000, Development of a syngeneic mouse model for events related to ovarian cancer: Carcinogenesis, v. 21, no. 4, p. 585-591.

31. Rodriguez, G. C. et al., 1999, Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: American Journal of Obstetrics and Gynecology, v. 164, no. 3, p. 745-750.

32. Sakayori, M. et al., 1990, Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma: Human Cell, v. 3, p. 52-56.

33. Shao, M. et al., 2009, Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase: Cancer Research, v. 69, no. 24, p. 9192-9201.

34. Shaw, T. J. et al., 2006, Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer: Molecular Therapy, v. 10, p. 1032-1042.

35. Steinmeyer, C. et al., 2003, The expression of hCG receptor mRNA in four human ovarian cancer cell lines varies considerably under different experimental conditions: Tumour Biol, v. 24, p. 13-22.

36. Taniguchi, T. et al., 2003, Disruption of the fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors: Nature Medicine, v. 9, p. 568-574.

37. Urzua, U. et al., 2010, Microarray proteomic analysis discriminates tumorigenic mouse ovarian surface epithelial cells of divergent aggressive potential: Molecular Biosystems, v. 6, no. 12, p. 2521-2528.

38. van der Berg-Baker, C. A. et al., 1993, Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: Growth features and cytogenetics: International Journal of Cancer, v. 53, no. 4, p. 613-620.

39. Wilson, A. P. et al., 1996, Characterisation of seven human ovarian tumour cell lines: British Journal of Cancer, v. 74, p. 722-727.

40. Yip, K. W. et al., 2006, Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent: Molecular Cancer Therapeutics, v. 5, no. 9, p. 2234-2240.



41. Yu, D. et al., 1992, Enhanced c-erb B-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A: Cancer Research, v. 53, p. 891-898.



Share with your friends:


The database is protected by copyright ©dentisty.org 2019
send message

    Main page